

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: J. Henkin, et al.

Serial NO.: (not yet

assigned)

Filed: April 11, 2001

Title: PEPTIDE ANTIANGIOGENIC

DRUGS

Case No.: 6356.US.P4

Group Art No.: (not yet

assigned)

Examiner: (not yet assigned)

Express Mail No.: EL384171800US

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service as Express Mail Post Office under 37 C.F.R. 1.10 addressed to:

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: April 11, 2001

Tanya Benavidez Date

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

This submission does not represent that a search has been made or that no better art exists, and does not constitute an admission that each or all of the listed documents are material or constitute "prior art". If it should be determined that any of the listed documents do not constitute "prior art" under

United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

ABBOTT LABORATORIES
D-0377/AP6D-2
100 Abbott Park Road
Abbott Park, IL 60064-3500
Telephone: (847) 937-0042
Facsimile: (847) 938-2623

Respectfully submitted, J. Henkin, et al.

Gregory W. Steele

Registration No. 33,796 Attorney for Applicants